Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 22, 2020
Daily News
July 22, 2020
- Chuikyo OKs Plan for September Drug Price Survey, Smaller Coverage amid COVID-19
July 22, 2020
- Japan to See Arrival of 1st Treatment for HFpEF, Will Entresto Meet Unmet Medical Needs?
July 22, 2020
- Chiome to Launch First-in-Human Trial for Anti-DLK-1 Antibody
July 22, 2020
- Shonan iPark’s VC Consortium Now Up and Running
July 22, 2020
- 9-Valent HPV Vaccine Hits Finish Line, but Japan Launch Schedule Uncertain with High Global Demand
July 22, 2020
- Mochida, Shimane Univ. Start Collaborative Research on New Treatment for Joint Disease
July 22, 2020
- Reinstate “Active Recommendation” for HPV Vaccines: LDP Lawmakers’ League
July 22, 2020
- Daiichi Sankyo’s Prasugrel Hits Primary Goal in Japan PIII for Thrombotic Stroke, Filing for Label Expansion Planned in 2021
July 22, 2020
- MSD Launches Injectable Version of Deep Mycosis Drug Noxafil
July 22, 2020
- Label Revisions Ordered for Iopamiron, 5 Other Contrast Media
July 22, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…